Best Small Cap Stocks to Trade

Small Cap Stock Alerts in Real Time | No one provides consistent winners like Broad Street!

Apr 12 2017

What Happened to Valeant Pharmaceuticals?

It is interesting to see what is happening to Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) ever since activist investor Bill Ackman announced that he had gotten rid of his stake in the pharmaceutical giant from Canada at a loss amounting to reportedly USD $ 2.8 billion or possibly even more. Bill Ackman’s Pershing Square Capital Management was the largest individual shareholder in the company spending an inordinate amount of time on a vast and expensive, highly publicised campaign to rejuvenate the stock price, which had declined by more than 90% since the commencement of the investment in the company. Mr Ackman pointed out the failed nature of the company business model, in which acquired assets were financed through borrowing, and success relied on product price increases before generics cut into market share. Since selling the stake, Ackman has been a strong critic of strategic errors from former CEO Michael Pearson and now feels that the time and effort required to revive and revitalized company may not be worth it.

 

What is wrong at Valeant

 

Mr. Pearson may be gone but investors were disappointed earlier this month when news broke that current CEO Joseph Papa took home a combined $62.7 million. This included a base salary of $980,769 a bonus worth $9.125 million and stocks and options worth nearly $52 million.

This was while Valeant’s stock lost nearly 62% of its value over the past year.

 

As at the end of December 2016, the company had $ 30 billion in debt balance by only $ 2 billion in operating cash flow and $ 3 billion in equity. At first glance, it would appear that the company will be unable to handle its debt problems and return value to investors. Most of the smart professional fund managers have fled the stock. While not following these professionals blindly, it is important to see how they act, especially if they have money in the game which they risk losing. Until recently, the stock was owned by most of the big hedge funds. The Sequoria Fund sold its stake, which costs the fund, $ 1 billion and ended the long career of manager Robert Goldfarb. Now Bill Ackman, till recently the biggest defender off the company, sold his stake acquired at an average of $ 196 a share for around $ 11 a share and the resulting loss of $ 2.8 billion is one of the biggest losses in the history of hedge funds. It looks as if fund managers have decided to sell to recover whatever money they can and only a few of the faithful, such as John Paulson remain.

____________________________________________________________________

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone***

_____________________________________________________________________

Investors should worry because Jim Chanos is arguably one of the most famous short sellers and contrarian investors and is reportedly short on the stock. He has shown a talent for finding problems in regulatory findings overlooked by many other investors and is famous for shorting stocks at their peak at a time when they are loved by Wall Street. Eventually, of course, the reality catches up, the stock price drops and Chanos takes his profits. He has compared this company with Enron at a time when the stock was a darling of Wall Street. He started shorting VRX when it is trading at $ 100 per share, noting that the lack of organic growth, the acquisition spree and aggressive accounting policies made him unhappy. Under previous CEO Michael Pearson, VRX did little drug research with R&D spending only around 3% of sales. Instead of the norm of 15% to 20%. Instead, the company would pile on debt to buy existing pharma companies and show profitability by reducing R&D spending and raising the prices of the acquired drugs.

 

Many people disliked the controversial strategy, including politicians who got the Senate to summon the company to Capitol Hill to question them about drug pricing. Long time Warren Buffett associate Charlie Munger accused the company of robbing hospitals. The company then promised to cut prices, even though some hospitals complained that they had achieved no cost savings. Moreover, a criminal probe was opened last year into the company and its relationship with Philidor the company in the mail order pharmacy business.

 

The financial problems

 

The growth by acquisition financed by large amounts of borrowing left it with a humongous amount of debt of around $ 30 billion. In contrast, the market capitalisation is only $ 3.71 billion and the revenue last year was only $ 9.67 billion. Metrics such as debt to equity of 9.47 and operating cash flow to that of 0.0699 do not look impressive. Moreover, the company made the inexplicable decision to take on a further $ 10 billion in debt as its stock price reached a high of $ 200 a share in March 2015. Prudence would have dictated an equity offering at high stock prices instead of additional debt. Twice last year, the company had to strike deals with creditors to relax the terms of its debt covenants and one third of the $ 10 billion in debt is floating rate borrowing. In an era where interest rates are expected to rise, an additional 100 basis points in interest rates will increase the interest bill by another $ 100 million.

 

Conclusion

 

While VRX stock has certainly disappointed many hedge fund and individual investors with a monumental stock price fall, and a bleak looking financial future, it should be noted: the VRX product pipeline has many products including household names like Bausch & Lomb and Wellbutrin. The current stock price is near a 9-year low and close to its book value. Annual revenues are still almost $10 billion and as recently as March 23, 2017, RBC Capital Markets issued a “sector perform” rating with a target of $18-23. The company was founded in 1983 and is headquartered in Laval, Canada.

 

 

Source: Broad Street Alerts Editor

 

About Broad Street Alerts

Big Opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

 

January 31st, 2017- (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

 

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

 

March 6th, 2017- (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

 

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

Written by broadAdmin · Categorized: applenews · Tagged: Remove term: Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) Valeant Pharmaceuticals, Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), VRX, VRX news

Privacy Policy and Disclaimer

Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
Cookie Policy
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Online Privacy Policy Only
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may reply to this email.
DISCLAIMER
This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.

Copyright © 2021 · Broad Street Alerts · All Rights Reserved